1 – 10 of 32
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Emerging pharmacotherapies for Parkinson's Disease: Experimental studies in the rat
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Novel strategies for enzyme replacement with gene therapy in models of Parkinson’s disease
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Chapter 22 - Rodent Models of Treatment-Related Complications in Parkinson Disease
2014) p.373-386(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2013
-
Mark
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
- 2012
-
Mark
Synthesis of C-1 indol-3-yl substituted tetrahydroisoquinoline derivatives via a Pictet-Spengler approach
(
- Contribution to journal › Article
-
Mark
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
(
- Contribution to journal › Scientific review
-
Mark
Duration of L-dopa and dopamine agonist monotherapy in Parkinson´s disease
(
- Contribution to journal › Article
-
Mark
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
(
- Contribution to journal › Article
-
Mark
Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain
(
- Contribution to journal › Scientific review
- 2011
-
Mark
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia
(
- Contribution to journal › Article